Kyle Rogers, MD
Ophthalmology · Enid, OKNPI 1750760609
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Rayner Intraocular Lenses Limited accounts for 96.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $12,174 and has fallen 98.3% since, to $203 in 2025. Among ophthalmology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $391.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rayner Intraocular Lenses Limited$18K
- Alcon$312
- Astellas Pharma US Inc$77
- AbbVie$61
- Regeneron Healthcare Solutions, Inc.$48
- Harrow Eye, LLC$41
- plus $149 from 7 others
What the payments were for
- Consulting fees$4,75225%
- Speaking & faculty fees$10,09853%
- Travel & lodging$3,21617%
- Food & beverage$1,0966%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rayner Intraocular Lenses Limited | 17 | $18,473 |
| Alcon | 13 | $312 |
| Astellas Pharma US Inc | 3 | $77 |
| AbbVie(2 entities) | 4 | $61 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Harrow Eye, LLC | 2 | $41 |
| Glaukos Corporation | 1 | $32 |
| Omeros Corporation | 2 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Merz North America, Inc. | 1 | $19 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RayOne EMV$11,911
- RayOne Spheric$11,911
- RayOne Aspheric$11,911
- OMIDRIA$6,404
How this compares
$19,162 in reported general payments places this provider in the 95th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 32 | $11,999 |
| RestasisCyclosporine | 17 | $10,537 |
| LumiganBimatoprost | 16 | $10,205 |
| Prednisolone Acetate | 340 | $9,935 |
| MoxifloxacinMoxifloxacin Hcl | 310 | $7,867 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $6,735 |
| Brinzolamide | 39 | $5,798 |
| Latanoprost | 430 | $3,853 |
| Timolol MaleateTimolol Maleate/Pf | 13 | $3,438 |
| Brimonidine Tartrate | 218 | $3,271 |
| Diclofenac Sodium | 313 | $3,142 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $1,606 |
| Dorzolamide Hcl | 55 | $1,295 |
| ErythromycinErythromycin Base | 120 | $1,265 |
| Timolol Maleate | 131 | $1,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $61 | $20,74233 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $22 | $18,73444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Enid
- David ZuechEnid$4K
- Ronald RebenitschOklahoma City$141K
- Don NguyenEdmond$36K
- Bradley BrittonEdmond$25K
- Edward JonesOklahoma City$13K
- John BelardoOklahoma City$12K
- David KorberOklahoma City$11K
- Jeffrey ShaverEdmond$11K
- Shehzad BatliwalaTulsa$11K
- Whitney PotterEdmond$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.